MARKET

FWBI

FWBI

First Wave Biopharma Inc
NASDAQ
9.24
+1.35
+17.11%
Pre Market: 6.85 -2.39 -25.87% 08:20 03/04 EST
OPEN
7.89
PREV CLOSE
7.89
HIGH
9.35
LOW
7.81
VOLUME
1.89K
TURNOVER
0
52 WEEK HIGH
85.00
52 WEEK LOW
2.750
MARKET CAP
14.42M
P/E (TTM)
-0.0475
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
Quoin Pharmaceuticals (NASDAQ:QNRX) stock rose 71.1% to $4.74 during Monday's pre-market session. The company's market cap rose to $1.6 billion. Helius Medical Tech shares increased by 55.04% and Renalytix stock rose 43.26% during the same period.
Benzinga · 1h ago
First Wave BioPharma, Inc. To Raise ~$4M Of Gross Proceeds In Registered Direct Offering Of 525,625 Shares Of Common Stock At A Price Of $7.61 Per Share
First Wave BioPharma, Inc. Is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. The company has entered into a definitive securities purchase agreement with a certain institutional investor. The Company will sell 525,625 shares of its common stock at a price of $7.61 per share.
Benzinga · 1h ago
Weekly Report: what happened at FWBI last week (0226-0301)?
Weekly Report · 5h ago
Weekly Report: what happened at FWBI last week (0219-0223)?
Weekly Report · 02/26 09:38
Weekly Report: what happened at FWBI last week (0212-0216)?
Weekly Report · 02/19 09:38
Weekly Report: what happened at FWBI last week (0205-0209)?
Weekly Report · 02/12 09:35
Weekly Report: what happened at FWBI last week (0129-0202)?
Weekly Report · 02/05 09:38
Weekly Report: what happened at FWBI last week (0122-0126)?
Weekly Report · 01/29 09:35
More
About FWBI
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. It is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.

Webull offers First Wave BioPharma Inc stock information, including NASDAQ: FWBI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FWBI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FWBI stock methods without spending real money on the virtual paper trading platform.